NEJM A TRIAL OF LOPINAVIR-RITONAVIR IN ADULTS

 

No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. METHODS We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19...

UC IRVINE WESTERN JOURNAL OF EMERGENCY MEDICINE: INTEGRATING EMERGENCY CARE WITH POPULATION HEALTH

 

Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department...

HYDROXYCHLOROQUINE AND AZITHROMYCIN AS A TREATMENT OF COVID-19: RESULTS OF AN OPEN LABEL NON-RANDOMIZED CLINICAL TRIAL

Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads...

NEJM CLINICAL OUTCOMES OF HYDROXYCHLOROQUINE IN HOSPITALIZED PATIENTS WITH COVID-19: A QUIASI - RANDOMIZED COMPARATIVE STUDY

 

Off-label use of hydroxychloroquine in the SARS-CoV-2 positive population has become widespread with only empirical evidence on its efficacy. This study addresses the efficacy of hydroxychloroquine on serological and supportive care measures in a hospitalized population...